Sterling Joins Innovate UK Programme to Investigate AI-Powered Biocatalysis Development

Sterling Pharma Solutions is delighted to announce its  participation in a new £4m Innovate UK funded programme, investigating AI-powered biocatalysis development, as part of the Sustainable Medicines Manufacturing Innovation Programme (SMMIP).

The project, named “Biocat Copilot – Digital Biocatalysis for Sustainable Medicines Manufacturing” is being led by biocatalysis specialist, Disyn Biotec. It will deliver an integrated digital AI ecosystem that transforms biocatalysis from a niche specialty into a readily accessible, predictable, and rapidly implementable strategy for sustainable API manufacturing.

“We will leverage our proven expertise in process development, scale-up and manufacturing to drive the development and demonstration of this innovative platform.” said Sam Brogan, Director of Global Research and Development at Sterling Pharma Solutions. “The programme will compliment and further strengthen our capabilities in designing biocatalytic routes for target APIs and streamline the integration of biocatalysis into GMP manufacturing, reinforcing our commitment to advancing sustainable and efficient pharmaceutical production.”

Innovate UK’s SMMIP aims to transform the UK’s medicines manufacturing sector by driving innovation, adoption, investment, and collaboration. The programme will focus on developing disruptive technologies to optimise the production of medicine and align with global sustainability goals.

The project is to be delivered in collaboration with leading partners across the UK pharmaceutical sector, including Imperagen, Prozomix, GSK, Bistol Myers Squibb, Britest, Dayhoff Labs UK, Bridge CMC, The University of Manchester, and The Biorenewables Development Centre.